Saturday, July 11, 2026

Patent directory · USPTO A61K / A61P

Patents matching “ala”

271 pharma patents match "ala" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 271
Index total 30,257
Page 1 / 12

Quick answer

This filtered view shows 271 pharmaceutical patents matching "ala" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

271 results for “ala” · 30,257 patents in full index Clear search

  1. WO 2026078615

    ASSOCIATION DE TALAZOPARIB ET D'ENZALUTAMIDE DANS LE TRAITEMENT DU CANCER DE LA PROSTATE MÉTASTATIQUE RÉSISTANT À LA CASTRATION

    PFIZER [US] · Granted Apr 16, 2026 · Expires Apr 11, 2046

    granted
  2. WO 2026078619

    ASSOCIATION DE TALAZOPARIB ET D'ENZALUTAMIDE DANS LE TRAITEMENT DU CANCER DE LA PROSTATE MÉTASTATIQUE RÉSISTANT À LA CASTRATION

    PFIZER [US] · Granted Apr 16, 2026 · Expires Apr 11, 2046

    granted
  3. WO 2026062034

    NANOPARTICULES DE PROTÉINE AFFICHANT DES ANTIGÈNES DE MALADIE DE LYME

    BAVARIAN NORDIC AS [DK] · Granted Mar 26, 2026 · Expires Mar 21, 2046

    granted
  4. WO 2026025082

    MÉTHODES DE TRAITEMENT DE LA MALADIE D'ALZHEIMER

    BIOGEN MA INC [US] · Granted Jan 29, 2026 · Expires Jan 24, 2046

    granted
  5. WO 2025242689

    MÉTHODES DE TRAITEMENT D'UNE MALADIE RÉNALE MÉDIÉE PAR APOL1

    ASTRAZENECA AB [SE] · Granted Nov 27, 2025 · Expires Nov 22, 2045

    granted
  6. WO 2025184490

    N-[4-FLUOR-5-[[(2S,4R)-4-[(6-MÉTHOXY-4-PYRIMIDNYL)OXY]-2-MÉTHYL-1-PYRROLIDINYL]MÉTHYL]-2-THIAZOLYL]ACÉTAMIDE DESTINÉ À ÊTRE UTILISÉ DANS LE TRAITEMENT DE LA MALADIE D'ALZHEIMER

    BIOGEN MA INC [US] · Granted Sep 4, 2025 · Expires Aug 30, 2045

    granted
  7. US 12385026

    Stabilized alpha-galactosidase and uses thereof

    Protalix Ltd. · Granted Aug 12, 2025 · Expires Aug 7, 2045

    granted
  8. US 12383516

    Albuterol aerosol suspension formulation for oral inhalation with high amount of green propellant hydrofluoroolefin (HFO) and free of co-solvent

    Amphastar Pharmaceuticals, Inc. · Granted Aug 12, 2025 · Expires Aug 7, 2045

    granted
  9. US 12350270

    Antimalarial agents

    MSD R&D (China) Co. Ltd. · Granted Jul 8, 2025 · Expires Jul 3, 2045

    granted
  10. US 12338219

    Antimalarial agents

    MSD R&D (China) Co. Ltd. · Granted Jun 24, 2025 · Expires Jun 19, 2045

    granted
  11. WO 2025111408

    COMPOSÉS POUR LE TRAITEMENT DE L'AMYOTROPHIE SPINALE ET DE LA MALADIE DE HUNTINGTON

    BIOGEN MA INC [US] · Granted May 30, 2025 · Expires May 25, 2045

    granted
  12. US 12286405

    Scalable synthesis of dual-target inhibitor of cannabinoid-1 receptor and inducible nitric oxide synthase

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Apr 29, 2025 · Expires Apr 24, 2045

    granted
  13. US 12274710

    Compound for regulating body weight imbalance, composition thereof and application thereof

    GUANGZHOU CENTURY CLINICAL RESEARCH CO., LTD · Granted Apr 15, 2025 · Expires Apr 10, 2045

    granted
  14. US 12268700

    3-o-sulfo-galactosylceramide analogs as activators of type II NKT cells and uses thereof

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Apr 8, 2025 · Expires Apr 3, 2045

    granted
  15. WO 2025068985

    DÉRIVÉS DE 1-(1-OXO-1,2-DIHYDROPHTALAZIN-6-YL)CYCLOALKYL-1-CARBOXAMIDE UTILISÉS EN TANT QU'INHIBITEURS COOPÉRATIFS DE MTA DE PRMT5

    BEIGENE SWITZERLAND GMBH [CH] · Granted Apr 3, 2025 · Expires Mar 29, 2045

    granted
  16. WO 2025064824

    MÉTHODES DE TRAITEMENT DE LA MALADIE D'ALZHEIMER

    BIOGEN MA INC [US] · Granted Mar 27, 2025 · Expires Mar 22, 2045

    granted
  17. WO 2025051711

    TRAITEMENT PAR PTH D'UNE MALADIE RÉNALE CHRONIQUE

    ASCENDIS PHARMA BONE DISEASES AS [DK] · Granted Mar 13, 2025 · Expires Mar 8, 2045

    granted
  18. WO 2025027051

    INHIBITEURS DE SPHINGOSINE-1-PHOSPHATE LYASE DESTINÉS À ÊTRE UTILISÉS DANS LE TRAITEMENT DE MALADIES NEURODÉGÉNÉRATIVES

    AB SCIENCE [FR] · Granted Feb 6, 2025 · Expires Feb 1, 2045

    granted
  19. US 12208167

    Coated tablets for pH-dependent release of benzgalantamine

    ALPHA COGNITION INC. · Granted Jan 28, 2025 · Expires Jan 23, 2045

    granted
  20. US 12194079

    Therapeutic regimen for the treatment of Fabry using stabilized alpha-galactosidase

    Protalix Ltd. · Granted Jan 14, 2025 · Expires Jan 9, 2045

    granted
  21. WO 2024242579

    RÉGIMES DE TRAITEMENT DE LA MALADIE DE PARKINSON IDIOPATHIQUE PRÉCOCE

    BIAL PORTELA & CA SA [PT] · Granted Nov 28, 2024 · Expires Nov 23, 2044

    granted
  22. US 12145925

    Phthalazine derivatives as inhibitors of PARP1, PARP2, and/or tubulin useful for the treatment of cancer

    The Regents of the University of California · Granted Nov 19, 2024 · Expires Nov 14, 2044

    granted
  23. US 12109258

    Synthetic malaria immunogens, combinations thereof, and their use to prevent and treat malaria infections

    Inovio Pharmaceuticals, Inc. · Granted Oct 8, 2024 · Expires Oct 3, 2044

    granted
  24. US 12102668

    Process, tube and device for the preparation of wound healant composition

    RegenLab USA LLC · Granted Oct 1, 2024 · Expires Sep 26, 2044

    granted